
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. demonstrated strong performance in Q4, with shares rising approximately 7% in the after-market following impressive results and positive revenue guidance, alongside operating margin expansion projected to exceed 16%. The company is poised for growth driven by new product launches, accelerated adoption rates in heart and lung transplants, and robust international market expansion, alongside favorable trends in organ utilization. Additionally, TransMedics is establishing a new standard of care within the organ transplant sector, presenting substantial value creation potential in the years ahead despite increasing competition.
Bears say
TransMedics Group Inc. is facing a negative outlook primarily due to projected declines in operating margins, anticipated to drop by 250 basis points this year as a result of significant investments in its clinical pipeline and international infrastructure. While the company reported strong revenue growth in its liver franchise, the overall product and service revenues fell short of consensus expectations, with significant underperformance in gross margins at 58.8%, missing targets by 180 basis points. Additional risks such as potential market share loss from increasing competition, reimbursement changes, and challenges in clinical trial execution further contribute to the financial uncertainties surrounding the company's future performance.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares